Ketamine Therapy

Fibromyalgia Care Breakthrough: DEA Green Lights Biotech Partnership Exploring Ketamine Implant Therapy
Pete Davidson Reveals He's Tried Ketamine To Cope With Depression
Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next
Pete Davidson Reveals He's Tried Ketamine To Cope With Depression
Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next
PharmaTher's Novel Ketamine Heads For The US Market With New Collaboration Agreement
In-Clinic Ketamine Businesses Are Shutting Down All Across The US, A Rising Trend?

Ketamine Therapy Recent News

Zappy Zapolin's Psycheceutical Files Patent, Hopes Ketamine Topical Can Treat PTSD
Lifesciences biotech company Psycheceutical Bioscience (OTC: BWVI), of which Benzinga’s advisory council member Zappy Zapolin is Chief Vi
Two New Studies On Classical Psychedelics: Grading Ketamine's Components, Tuning Down Psilocybin Dosing
Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect
Here Are The Latest Psychedelics Partnerships From Production & Supply Chain To Community Action
Let’s do a quick tour of some of the latest announcements made by psychedelics companies over the past week. We promise you’ll be informed in less time than it takes to brew your coffee. New, Standardized Magic Mushroom Microdosing Capsules By Red Light Holland And Partner CCrest Labs
2 Psychedelics Companies Tout Advanced Clinical Trials, Progress With Key Products
Two psychedelics companies have shared their updates and key milestones to be reached this 2023.
atai Life Sciences' Drug Trial For Depression Fails To Deliver Expected Results, Stock Plunges
Clinical-stage psychedelics biotech atai Life Sciences (NASDAQ: ATAI) shared the results of its NYC-based subsidiary NYC-based Perception Neuroscience’s Phase 2a study of proprietary R-ketamine PCN-101 on patients with Treatment-Resistant Depression (TRD.).
Awakn Unveils Q3 Results, Touts Revenue Growth, R&D Progress, Commercial Plans
Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022. Financials showed:
New Collaboration Will Bring Psychedelic Clinics & Retreats With Vertical Offerings To The U.S.
Ketamine-therapy provider Revitalist Lifestyle & Wellness Ltd.
Ketamine Therapy: Revitalist's New Financing Option, Irwin Naturals Expands Chain Of Clinics
Revitalist Increases Patient Access By Financing Costs With M-Lend Financial
What Are The Best Psychedelic-Assisted Therapy Clinics In The World? Here Are 5 To Check Out
Psychedelic-Assisted Therapy, or PAT, is the type of treatment in which the delivery of a psychedelic substance -i.e.
Psychedelics For Alzheimer's And Stress-Induced Disorders Under Study At Columbia University
Silo Pharma Inc.
Can Ketamine Treat Alcohol Addiction? In-Clinic Therapy Vs. Retreats
(Part four of a four-part series - Read part three)
Can Ketamine Treat Alcohol Addiction? This Is How Therapy Actually Functions
(Part two of a four-part series, see part one here)
Can Ketamine Treat Alcohol Addiction? Clinics & Hospitals In Europe And North America Are Already Doing It
(Part one of a four-part series) The use of psychedelic-assisted psychotherapy for the treatment of mental health conditions has become a hot topic, with a growing general sense of acceptance, public discussion and reform.
Ketamine Therapy Growing In US And Canada With This Novel Montreal Clinic
Legal ketamine-assisted therapy for people with diagnosed mental health conditions continues to expand throughout the U.S. and Canada. 
Awakn Enters U.S. Addiction Treatment & Relapse Prevention Market With Ketamine Therapy For Alcohol Use Disorder
Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company focused on addiction treatments, has signed a licensing partnership agreement with US ketamine therapy clinics owner Revitalist Lifestyle and Wellness Ltd.
At-Home Ketamine For Depression: New Study Adds Proof On Its Safety And Efficacy
Is At-Home Ketamine Treatment Safe For Patients?
KetaDASH Announces Mobile Ketamine Treatments in San Francisco and Sacramento Area
Ehave, Inc.
EXCLUSIVE: Pasithea Clinics Launches In-Home Intravenous Ketamine Therapy In Major US Cities
Pasithea Therapeutics Corp.
Investment Company Myconic Capital Agrees To Buy Mindscape Ketamine & Infusions Therapy
Myconic Capital Corp. (CSE: MEDI) agreed to buy Mindscape Ketamine & Infusions Therapy PLLC for $175,000.